COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE

被引：1
|
作者：
Solakidi, A. [1 ]
Tzanetakos, C. [1 ]
Maniadakis, N. [2 ]
机构：
[1] EVROSTON LP, Athens, Greece
[2] Natl Sch Publ Hlth, Athens, Greece
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2394
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS16
引用
收藏
页码：A803 / A803
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF APREMILAST IN MODERATE TO SEVERE PSORIASIS IN SCOTLAND
    Mughal, F.
    Cawston, H.
    Kinahan, D.
    Morris, J.
    Tencer, T.
    Zhang, F.
    VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [2] Cost-effectiveness of apremilast in moderate to severe psoriasis in the UK
    Mughal, Farhan
    Barker, Jonathan
    Cawston, Helene
    Damera, Vidya
    Bewley, Anthony
    Morris, James
    Shaw, Tim
    Tencer, Tom
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB243 - AB243
  • [3] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [4] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [5] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Kiri, S.
    Tzanetakos, C.
    VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [6] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [7] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [8] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [9] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [10] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Christou, P.
    Relakis, J.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S74 - S74
12345